![Medexus Pharmaceuticals Inc Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/tsx/mdp.png?tr=w-200)
Medexus Pharmaceuticals Inc
TSX:MDP
![Medexus Pharmaceuticals Inc Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/tsx/mdp.png)
Intrinsic Value
Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which provides healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease... [ Read More ]
The intrinsic value of one
MDP
stock under the Base Case scenario is
8.19
CAD.
Compared to the current market price of 1.65 CAD,
Medexus Pharmaceuticals Inc
is
Undervalued by 80%.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/tsx/mdp.png?tr=w-200)
Valuation Backtest
Medexus Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
MDP
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/tsx/mdp.png)
Balance Sheet Decomposition
Medexus Pharmaceuticals Inc
Current Assets | 74.1m |
Cash & Short-Term Investments | 8.2m |
Receivables | 22.2m |
Other Current Assets | 43.6m |
Non-Current Assets | 86.3m |
PP&E | 843k |
Intangibles | 76.8m |
Other Non-Current Assets | 8.7m |
Current Liabilities | 66.5m |
Accounts Payable | 43.4m |
Other Current Liabilities | 23.1m |
Non-Current Liabilities | 64.3m |
Long-Term Debt | 37.2m |
Other Non-Current Liabilities | 27.1m |
Earnings Waterfall
Medexus Pharmaceuticals Inc
Revenue
|
115.7m
USD
|
Cost of Revenue
|
-54.5m
USD
|
Gross Profit
|
61.2m
USD
|
Operating Expenses
|
-48.4m
USD
|
Operating Income
|
12.8m
USD
|
Other Expenses
|
-6.9m
USD
|
Net Income
|
5.9m
USD
|
Free Cash Flow Analysis
Medexus Pharmaceuticals Inc
MDP Profitability Score
Profitability Due Diligence
Medexus Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/tsx/mdp.png)
Score
Medexus Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
MDP Solvency Score
Solvency Due Diligence
Medexus Pharmaceuticals Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/tsx/mdp.png)
Score
Medexus Pharmaceuticals Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MDP Price Targets Summary
Medexus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
MDP
is 3.32 CAD
with a low forecast of 2.02 CAD and a high forecast of 6.2 CAD.
Shareholder Return
MDP Price
Medexus Pharmaceuticals Inc
Average Annual Return | -5.27% |
Standard Deviation of Annual Returns | 55.57% |
Max Drawdown | -91% |
Market Capitalization | 40.4m CAD |
Shares Outstanding | 24 458 213 |
Percentage of Shares Shorted | 0.08% |
Company Profile
![Medexus Pharmaceuticals Inc Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/tsx/mdp.png?tr=w-200)
![Medexus Pharmaceuticals Inc Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/tsx/mdp.png?tr=w-200)
Country
Industry
Market Cap
Dividend Yield
Description
Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which provides healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease and pediatrics. The company is headquartered in Bolton, Ontario and currently employs 79 full-time employees. The company went IPO on 2012-03-03. The firm is a North American focused, specialty pharmaceutical business that operates through two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada, a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. Medexus Pharma USA, a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States (U.S). The firm is focused on the therapeutic areas of auto-immune disease, hematology, pediatrics, dermatology and allergy. The firm's products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases. The company also offers IXINITY, a medicine for use in patients 12 years of age or older with Hemophilia B and Rupall, an allergy medication.
Contact
IPO
Employees
Officers
The intrinsic value of one
MDP
stock under the Base Case scenario is
8.19
CAD.
Compared to the current market price of 1.65 CAD,
Medexus Pharmaceuticals Inc
is
Undervalued by 80%.